10x Genomics, Inc.(TXG)— Stock Profile, AI Score & Financials

Technology · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

10x Genomics, Inc. (TXG) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores TXG at 40.5/100 on a 32-signal composite quality model, placing it at rank #2,100 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (19.4) and profitability (20.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), 10x Genomics, Inc. reports quarterly revenue of $151.0M, net income of $-17.9M, free cash flow of $15.4M. Top institutional holders of TXG by reported 13-F value include FMR, BlackRock, ARK Investment Management, based on the most recent SEC filings. TXG trades on the Nasdaq exchange and files with the SEC under CIK 1770787. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TXG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 10x Genomics, Inc. directly from SEC EDGAR.